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Abstract 
Glucan particles (GPs) are 2-4 um hollow, porous shells extracted from Baker’s 
yeast, Saccharomyces cerevisae. The GP surface is composed primarily of 1,3-B-glucan 
allowing for efficient receptor-mediated particle uptake by phagocytic cells expressing 
glucan receptors. GPs have been used for macrophage-targeted delivery of payload 
macromolecules (i.e. DNA, siRNA, protein). Mesoporous silica nanoparticles (MSNs) 
are materials synthesized from tetraorthosilicate reacting on a template to produce 
particles with a regular arrangement of pores. The large surface area of the MSN pores 
allows for efficient drug encapsulation. In this project, a model combined GP/MSN drug 
delivery system was developed using the chemotherapeutic drug doxorubicin (Dox) and 
the antibiotic rifampicin (Rif). The GP/MSN system benefits from the macrophage 
targeting capabilities of GPs and small drug molecule binding capacity of MSNs. 
GP/MSN samples containing Rif were studied for their effect on inhibiting E. coli 
growth. GP/MSN formulations containing Dox were evaluated for Dox delivery and 
growth arrest of the model murine cell line NIH3T3-D1.  
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1. Introduction 
This project was developed to establish experimental methods to prepare glucan 
particles (GPs) containing mesoporous silica nanoparticles (MSNs) for small drug 
molecule targeted delivery to macrophages. It is the goal of this project to synthesize GPs 
containing MSNs to create a delivery agent that benefits from the macrophage targeting 
capabilities of glucan particles and small drug molecule binding capacity of MSNs.   
 
1.1 Glucan particle delivery technology 
Delivery agents play crucial roles in the synthetic transportation of materials into 
cells. An effective delivery agent is defined by three key characteristics. First, the 
delivery agent must protect the material being transported and preserve the material from 
degradation. Second, the material needs to be successfully delivered into the target cells 
through the cell membrane.  The last characteristic is that the delivery agent should have 
minimal detrimental effects on the target cell (Soto & Ostroff, Characterization of 
Multilayered Nanoparticles Encapsulated in Yeast Cell Wall Particles for DNA Delivery, 
2008).  
 
In order to create empty shells that can be used for transportation, Baker’s yeast 
(Saccharomyces cerevisiae) is processed by chemical extractions into particles of 
different carbohydrate and lipid compositions. Baker’s yeast particles can be synthesized 
into delivery agents that are characterized as being hollow, biodegradable, porous 
particles that range from 2 – 4 µm in diameter (Figure 1). The primary carbohydrate 
composition of a Baker’s yeast particle is β-1, 3-D-glucan (~85%), glycogen, water and 
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ash, with <1% residual levels of chitosan/chitin, and mannoproteins (Young, et al., 2007).  
The high β-1, 3-D-glucan composition of the particle surface allows for efficient 
phagocytosis via receptor-mediated cell uptake by cells expressing glucan receptors 
(dectin-1 (D1) and complement receptor 3 (CR3 or CD11b/CD18)), such as monocytes, 
macrophages, neutrophils and dendritic cells (Brown & Gordon, 2001) . GP uptake has 
been demonstrated to be dectin-1 dependent in vitro as shown in Figure 2. Bone marrow 
dendritic cells (BMDC), from a wild type mouse, efficiently phagocytize fluorescently 
labeled GPs. BMDCs from a dectin-1 knockout mouse do not show GP uptake. 
Furthermore the addition of a laminarin, a soluble β -glucan, inhibits GP uptake in the 
wild type BMDCs. (Huang, Ostroff, Lee, Wang, Specht, & Levitz, 2009).  
 
Depending on the chemical extraction treatment (acid/base, organic solvent 
extraction) it is possible to obtain GPs of slightly different chemical compositions. Three 
examples of particles derived from Baker’s yeast include standard glucan particles (GPs), 
glucan mannan particles (GMPs), and glucan lipid particles (GLPs).  Standard GPs are 
composed primarily of β-1, 3-D-glucan and low levels of chitin. GPs have gone through 
the highest level of purification in comparison to the GMPs which still consists of β-1, 3-
D-glucan, mannoproteins, and chitin (Soto & Ostroff, Characterization of Multilayered 
Nanoparticles Inside Yeast Cell Wall Particles for DNA Delivery, 2008). The last 
variation of Baker’s yeast particles is the GLPs. GLPs also have β-1, 3-D-glucan and a 
low level of chitin, like the GP, but the GLP also has a lipid layer remaining. The lipid 
layer is predominantly composed of sterols (squalene, zymosterol, ergosterol and 
lanosterol) (Sajbidor & Gergoa, 1994). This lipid layer allows for better loading of 
hydrophobic compounds than the standard GPs 
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Glucan particles are an alternative non-viral macromolecular delivery vehicle. 
Macromolecules (i.e. DNA, siRNA, proteins, vaccines) can be trapped inside the hollow 
particle cavity by electrostatic interactions between the payload molecules and trapping 
polymers forming polyplexes. Depending on the location of the payload drug there are 
three possible GP-polyplex formulations as shown in Figure 3. The advantages of the 
glucan particle delivery system include, high binding capacity, as well as the co-
encapsulation of a wide variety of possible guest molecules in the polyplex structures 
with specific functions to facilitate payload release upon uptake of the GPs by target cells 
(Soto & Ostroff, Characterization of Multilayered Nanoparticles Inside Yeast Cell Wall 
Particles for DNA Delivery, 2008) (Aouadi, et al., 2009) (Soto & Ostroff, Oral 
Macrophage Mediated Gene Delivery System, 2007) (Tesz, et al., 2011).  
 
Glucan particles have also been used for the delivery of small drug molecules. 
However, since the majority of small drug molecules are neutral, monovalent in charge, 
or insoluble in water, such payloads are not effectively trapped within glucan particles 
using core or LbL encapsulation methods. Previous studies have shown the use of glucan 
particles for the delivery of small molecules using hydrogels to physically entrap the drug 
(i.e. rifampicin) inside the particles instead. These studies showed effective reduction in 
vitro of intracellular Tuberculosis levels in infected bone marrow derived macrophages 
with GP-Rif formulations at sub-MIC (minimum inhibitory concentration) levels of the 
antibiotic. However, the formulations were not effective for controlled drug release 
limiting its in vivo application (Soto E. , Kim, Lee, Kornfield, & Ostroff, 2010).  
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 Recent advances in glucan particle delivery technology include the ability to 
encapsulate pre-formed nanoparticles (NPs) of less than 30 nm in diameter into GPs and 
to non-covalently bind larger nanoparticles to the outer surface of a derivatized glucan 
particle (Figure 4). Nanoparticles of less than 30 nm (i.e. fluorescently labeled 20 nm 
polystyrene, 10 nm magnetic iron oxide NPs, and 10 nm quantum dot nanoparticles) have 
been efficiently trapped inside GPs. The advantages of nanoparticle encapsulation are: (1) 
it extends the applicability of the glucan particle delivery system by allowing 
encapsulation of materials that cannot be prepared in situ as the synthetic conditions are 
not compatible with glucan particles, (2) this allows for incorporation of nanoparticles 
that can enhance the ability to load small drug molecules (neutral, hydrophobic drugs) 
into GPs, and (3) it allows for incorporation of nanoparticles with an intrinsic property, 
such as magnetic nanoparticles, thus increasing the versatility of the particles, as the same 
formulation could be used for drug delivery and the magnetic properties employed for 
cell purification, or imaging applications (Soto & Ostroff, 2011) (Soto & Ostroff, Use of 
beta-Glucans for Drug Delivery Applications, 2011) (Soto & Ostroff, Encapsulation of 
Nanoparticles Inside Yeast Cell Wall Particles for Receptor-targeted Drug Delivery, 
2010). 
 
1.2 Mesoporous Silica Nanoparticles 
 Mesoporous silica nanoparticles (MSNs) were first developed in the labs of the 
Mobil Corporation in 1992 and originally named Mobil Crystalline Materials or MCM-
41 (Kresge, Leonowicz, Roth, Vartuli, & Beck, 1992). MSN was developed as an 
inorganic delivery agent.  These nanoparticles are of interest because of their high 
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chemical and thermal stability. MSNs are synthesized by reaction of tetraethyl 
orthosilicate (TEOS) and a template, which form nano-sized spheres or rods (Figures 5-
6).  The basic structure of a MSN is of a particle 50-500 nm in diameter with pores 
ranging from 2 to 20 nm in size. These pores are mostly cylindrical in shape (Kresge, 
Leonowicz, Roth, Vartuli, & Beck, 1992) but range in the level of order of their 
molecular organization. The basic structure of these molecules lends themselves to be 
used for absorption, catalysis, chemical expression, or for use in chemical devices 
(Trewyn, Slowing, Giri, Chen, & Lin, 2007). Through the process of different syntheses 
it is possible to control the morphology and porosity of these small cylindrical particles. 
Furthermore, MSN can be functionalized externally and internally with organic and 
inorganic groups due to its large internal and external surface areas.  
 
Since the discovery of MSN in 1992, scientists have been working to gain more 
control over its’ specific characteristics. More recent work has been focused on the 
controlled release and delivery of drugs. Chemical modification of MSN allows 
incorporation of functional groups to facilitate absorption of target compounds (i.e. 
cationic MSNs for binding of nucleic acids). Modification of the external surface of the 
MSN has been done to introduce targeting ligands. In these ways, MSNs can be modified 
to be taken up by a specific receptor mediated process by target cells to complete 
controlled release of genes and drugs within the cell. Limitations exist in this because the 
introduction of ligands to the nanoparticles is synthetically challenging and the MSNs are 
produced at a high expense with a low yield.  
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1.2.1 Mesoporous Silica Nanoparticle Synthesis 
 The basic synthesis of MSNs can be performed in acidic or basic 
conditions. The process begins with the surfactant, cetyltrimethylammonium bromide 
(CTAB), dissolved in water. Tetraethylorthosilicate (TEOS) is then added to this solution 
and heated for several hours. Following complete polymerization of the TEOS reagent, 
the CTAB is then extracted from the solution through reflux. By manipulating 
temperature, micelle formation, co-solvent and pH during this process, the size and shape 
of the nanoparticles that are generated can be controlled. It is important to complete the 
reaction at a low surfactant concentration to make the assembly of the MSN dependent 
upon the interactions between the cationic surfactant and the growing anionic oligomers 
of orthosilicic acid. This, in turn, will limit the MSN to a small size (Trewyn, Slowing, 
Giri, Chen, & Lin, 2007). The synthetic scheme of MSN using TEOS is depicted in 
Figure 5.  
 
Within a MSN there are two distinct surfaces including the external and internal 
surfaces, both of these surfaces can be further functionalized with active groups. There 
are two processes to functionalize the surfaces of MSN; the first process is called 
grafting. Grafting can be completed with post-synthesis nanoparticles to selectively 
functionalizing the exterior surface of the MSN. The organosilanes, 
organotrialkoxysilanes or organotrichlorosilanes, are reacted with the MSN in a non-
polar anhydrous solvent. This method usually leads to most of the organosilanes binding 
to the exterior of the MSN or in the openings of the pores (Trewyn, Slowing, Giri, Chen, 
& Lin, 2007). 
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 The second method for functionalizing the MSN is called the co-condensation 
method. In this direct synthesis method, a co-condensing agent is added to the aqueous 
CTAB and TEOS solution during condensation to control the shape of the MSN. The co-
condensing agent will allow for control of the morphology of the particles along with the 
type and degree of functionality. The characteristics of the co-condensing agent that 
should be considered include concentration, molecular size, and hydrophobicity or 
hydrophilicity. These properties will determine the ability of the co-condenser to 
influence the stabilization of the micelles during the formation of MSN.  
 
The formation of individual cylindrical micelles is stabilized by non-polar groups 
interacting with hydrocarbon tails of the surfactant templates. As a result, the charge 
density of the head group is reduced.  This group exhibits “side on” growth of the silicate 
coated cylindrical micelles, generating rod shaped nanoparticles. Both variations of MSN 
can be seen in Figure 6. On the other hand, when the co-condensing agent is more 
hydrophilic there is no further stabilization; therefore little “side on” condensation growth 
is seen. In this scenario, formation of long micelles is rendered. Small spherical particles, 
that resemble the molecules that were achieved with no co-condensation agent, are 
created instead (Trewyn, Slowing, Giri, Chen, & Lin, 2007).  
 
 Using the co-condensing method, it is possible to obtain monodisperse, multi-
functionalized MSN. The MSN can have the ability to tune the relative ratios of the 
functional group of interest.  In this process two different co-condensing agents are used 
that have diverse structure directing abilities. This allows the synthesis of particles with 
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specific pore and particle morphologies. By changing the ratios of the two organic 
functional groups used as co-condensing agents, one is able to control the shape and size.  
 
Also, it is possible to control functionality by changing concentrations of co-
condensing agents; not only can the type of functionality be altered but also the degree 
(Trewyn, Slowing, Giri, Chen, & Lin, 2007). Specifically, the surface of MSN has been 
modified to cap the pores to prevent rapid release, incorporation of magnetic 
nanoparticles for cell purification, or targeting ligands for a receptor mediated cell 
uptake. 
 
1.2.2 Mesoporous Silica Nanoparticles for Cancer Therapy 
For the most part, anticancer therapeutic drugs are hydrophobic in nature and 
therefore present challenges for optimal targeted delivery. Mesoporous silica 
nanoparticles are consequently important in the administration of these drugs to increase 
their aqueous solubility. It is highly important to first encapsulate the drug before (Gillies 
& Frechet, 2005) dispensation in order to overcome any issues with low solubility (Lu, 
Liong, Zink, & Tamanio, 2007).  
 
MSN has the advantage of having low toxicity. Cell uptake of MSN occurs 
mainly by an endocytosis process. Receptor targeted phagocytosis has been accomplished 
by further modification of the outside surface of MSN with targeting ligands. In order for 
the MSN to carry the hydrophobic cancer drugs, the drugs must first be suspended in 
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DMSO. This allows the drugs to be absorbed by the MSN and the DMSO can then be 
removed through washing and centrifugation.  
 
The application of MSN to deliver cancer drugs, as mentioned above, has already 
been successfully demonstrated with MSNs of 130 nm in size with 750 pores that were 
each about 2 nm in diameter. The particles were loaded with the hydrophobic anticancer 
drug camptothecin or the drug paclitaxel. Both of these drugs were successfully absorbed 
by the MSN and delivered to the target cells (Lu, Liong, Sherman, Xia, Kovochich, & 
Nel, 2007). In the mainstream pharmaceutical world, about 40% of drugs have low 
solubility in water; advances in MSN could vastly improve the efficiency and application 
of these drugs (Lu, Liong, Sherman, Xia, Kovochich, & Nel, 2007). 
 
1.3 Synthesis of Mesoporous Silica and Glucan Particles 
 Individually MSNs and GPs both contain useful drug delivery characteristics, but 
also have their limitations. MSNs have the ability to absorb both hydrophobic and 
hydrophilic small drug molecules, but have no cell targeting specificity unless the MSN 
is chemically modified to introduce targeting ligands. GPs have limitations in the binding 
of small drug molecules, especially hydrophobic drugs, but provide selective targeted 
delivery to innate immune cells (macrophage cells) that express glucan receptors. GPs 
also have a high binding capacity for pre-formed nanoparticles, making them a suitable 
encapsulation system for mesoporous silica-drug nanoparticles. The synergy of this 
approach is expected to create a successful delivery agent that benefits from (1) the 
binding capacity of MSNs and (2) macrophage targeted delivery by GPs. Specifically, in 
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this project, the drugs Rifampicin (Rif) and Doxorubicin (Dox) were incorporated into 
MSN-GPs formulations and delivered to macrophage cell lines and primary cells with 
glucan receptors.  
 
 The GPs were combined with MSNs through three different methods (Figure 7). 
The first method consisted of loading the pre-formed MSNs inside of the GPs; the second 
method included loading the soluble MSN reagents into the GPs followed by in situ 
synthesis of MSN; the third method included non-covalent binding of anionic or cationic 
MSNs to the modified surface of the GPs. 
 
1.3.1 Payload Drugs 
 Mesoporous silica nanoparticles were tested as drug delivery agents using two 
slightly hydrophilic drugs, Rifampicin (Rif) and Doxorubicin (Dox). The molecular 
structures of Rif and Dox can be seen in Figures 8 and 9. 
 
Rifampicin and doxorubicin were chosen for this project for specific reasons. 
Rifampicin is one of the few small drug molecules that has been previously studied with 
glucan particles (Soto E. R., Kim, Lee, Kornfield, & Ostroff, 2010).  Therefore, the GP-
MSN-Rif formulation results can be compared to the previous data.  Also, there are 
possibilities of research collaboration with groups at UMass Medical School working on 
tuberculosis (TB). This collaboration would potentially allow for the GP-MSN-Rif 
complexes to be tested in vitro with TB infected macrophage cells and in vivo in a TB 
murine infection model. 
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Doxorubicin was chosen because it is a fluorescent cancer drug. Fluorescence is 
ideal for quantitative and qualitative microscopic analysis of glucan particles 
encapsulated formulations. Dox is also an ideal drug to study because of its anti-tumor 
activity. A long-term goal of the project is to demonstrate the delivery of glucan particle 
encapsulated Dox into macrophages and using the macrophages as Trojan horse carriers 
of the GP-MSN-Dox formulation into tumors following macrophage migration into 
tumors. 
 
1.3.1.1 Rifampicin 
Rif is a semi-synthetic antibiotic that belongs to the chemical group of rifamycins. 
Rif is the first antibiotic of the ansamycin family and is a first-line agent used in the 
treatment of tuberculosis (TB). The drug was isolated in 1959 by Sensi et al. from a strain 
of Amycolatopsis mediterranei and was introduced into therapy in 1962 (Sensi, 
Margalith, & Timbal, 1959). The antimicrobial activity of Rif is a direct result of its 
inhibition of bacterial RNA polymerase (RNAP). Rif binds to conserved amino acids in 
the active center of the enzyme and blocks transcription initiation. One limitation with the 
use of this drug is the resistance to Rif due to mutations of the amino acids that Rif binds 
to (Tupin, Gualtieri, Roquet-Baneres, Morichaud, Brodolin, & Leonetti, 2010).  
 
In order to achieve enhanced uptake of Rif into target cells and to reduce the drug 
dosage, new targeted drug delivery methods have been studied, since the drug can be 
toxic in high concentrations. Nanoparticle and microparticle-based delivery vehicles have 
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been used for the delivery of Rif. These vehicles include liposomes, PLGA microparticles 
and nanoparticles, and dendrimers. In previous work, Rif was encapsulated in GPs to 
demonstrate targeted delivery to alveolar macrophages, the primary replication site of 
TB. In order to delay the release of the drugs from the microparticles, the pores of the 
GPs were sealed using an alginate or chitosan hydrogel. The hydrogel seal of the GPs 
was able to extend drug release for 24-72 hours. Also, it has been shown that the effect of 
GP targeted Rif delivery to macrophages enhances Rif antimicrobial effects. (Soto E. , 
Kim, Lee, Kornfield, & Ostroff, 2010). Limitations of these formulations were observed 
in this study due to low Rif loading and lack of control over timed release.  
 
1.3.1.2 Doxorubicin 
Doxorubicin (Dox), also commonly referred to as adriamycin or 14-
hydroxydaunorubicin, is an anthracycline-type anti-tumor drug that acts against cancer 
cells. Clinical studies of Dox began in 1969 under the direction of Dr. Gianni Bonadonna 
of the Instituto Nazionale per lo Studio e la Cura dei Tumori in Milan, Italy (Bonadonna, 
Monfardini, De Lena, Fossati-Bellani, & Beretta, 1970). In the mid 1970s clinical trials 
began in the United States after the discovery of the drugs antitumor activity. Thus far, 
Streptomyces peucetius ATCC 27952 is the only known organism known to produce 
Dox. Doxorubicin is a popular cancer drug because it exerts antiproliferative activity on 
cancer cells via two different mechanisms. The two mechanisms are intercalation and 
enzyme inhibition which both result in DNA disruption and eventually cell death 
(Niraula, Kim, Sohng, & Kim).  
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Presently, Dox is an antibiotic widely used in cancer chemotherapy. However, 
there are a few limitations in the use of Dox as an antitumoral agent. The first limiting 
factor is the drugs chronic or acute cardiotoxicity. Cardio effects of Dox are expressed by 
changes in the electrocardiogram, which are generally reversible, but can cause a 
congestive heart failure resulting in death. The affinity of Dox towards negatively 
charged phospholipids could partially explain the cardiotoxic effect of the drug. Another 
limiting factor is the spontaneous or acquired resistance to the drug. The cause of this 
resistance is related to the modification of the cell membrane (Aubel-Sadron & Londos-
Gagliardi, 1984). 
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2. Materials and Methods 
Materials: All chemicals for the synthesis of MSN were purchased from Sigma 
Aldrich and Fischer Scientific and used as received. Glucan lipid particles (GLPs) and 
glucan particles (GPs) were prepared in the Ostroff laboratory using Baker’s yeast 
(Fleishmans Baker’s yeast, AB Mauri Food Inc., Chesterfield, MO, or from SAF-
Mannan, Biospringer, Juno, WI). All materials for cell tissue culture experiments were 
purchased from Gibco Scientific or Fischer Scientific. The purity of rifampicin and 
doxorubicin drugs used for the evaluation of MSN samples was corroborated by 
measuring of the UV/Vis absorbance spectra of rifampicin (Appendix A) and the 
fluorescence excitation/emission spectra of doxorubicin (Appendix B). 
 
Equipment: Spectrophotometric assays were measured with Safire Tecan 2 plate 
reader. Fluorescence microscopy images were obtained with a Zeiss Axiovert 200 
microscope equipped with a Zeiss AxioCam HR CCD camera with 1300x1030 pixel 
resolution. GP/MSN samples were evaluated at a 100x magnification. Experiments with 
cells on 24-well plates were evaluated at a 20x magnification. 
 
2.1 Synthesis of Mesoporous Silica Nanoparticles 
 Several classes of MSN were synthesized to have a collection of material with 
different functionalities. The different MSN compositions are listed in Table 1. All MSNs 
were made from commercially available materials with the exception of the fluorescent 
MSN, for which fluorescent-APTS (f-APTS) was synthesized.  
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Synthesis of Fluorescent-APTS (f-APTS):  
Amino-propyltriethoxysilane (200 L) was reacted with fluorescein 
isothiocyanate (FITC, 7.3 mg) in 1 mL of ethanol. The reaction mixture was stirred under 
nitrogen for two hours. The reaction mixture was stored at -80 °C until ready to use for 
MSN synthesis. f-APTS samples in ethanol were stored for no more than two weeks. 
 
Mesoporous Silica Nanoparticles (MSNs): 
A solution containing cetyl trimethylammonium bromide (CTAB, 3.5 g) in water 
(168 mL) and NaOH (2 M, 1.2 mL) was heated at 80°C and stirred vigorously until the 
solutes were dissolved. 24 mL of the CTAB solution was added to six different 50 mL 
centrifuge tubes. Each tube was placed in a hot water bath on a hot/stir plate and stirred 
vigorously. A solution containing the MSN reagents (tetraethylorthosilicate, TEOS or 
amino-propyltriethoxysilane APTS) was prepared as shown in Table 1. Once the 
solutions reached 80 °C the APTS/TEOS solutions were added and stirred at 80 °C for 15 
minutes. 3-trihydroxysilylpropyl methylphosphonate (PO4) was added to and the 
solutions were left to incubate for 2 hours at 80 °C with stirring. 
 
The solutions were cooled to room temperature and then centrifuged for 20 
minutes. The particles were washed using 50 mL of methanol and centrifuged for an 
additional 15 minutes. The particles were left to dry overnight. The CTAB was extracted 
from the MSN by refluxing the particles (850 mg) in an acidic methanol mixture (90 mL 
of methanol and 5 mL of 12.1 M HCl) for 24 hours. The particles were then washed with 
50 mL of methanol three additional times and left to dry overnight. 
WORCESTER POLYTECHNIC INSTITUTE  23 
 
A negative TEOS control sample (MSN-7) was prepared by reacting TEOS (2.5 
mL) in a solution containing only NaOH (no CTAB) at 80 ˚C for two hours with 
continuous stirring. The sample was then cooled to room temperature and placed in the 
negative 80 ˚C freezer before being lyophilized. The product was washed three times 
with 50 mL of water and three times with 50 mL of methanol. The final product was left 
to dry overnight at room temperature. 
 
2.2 Synthesis of Cationic Glucan Particles 
Three 15 mL tubes were prepared with 15 mg of GPs. The particles were 
resuspended in 10 mL of deionized water. The samples were centrifuged and the water 
was discarded. 600 µL of a 1 mg/mL solution of potassium periodate and 2.4 mL of 
water was added to the samples and the mixture was left stirring in a dark room at room 
temperature over night. The solutions were centrifuged and the supernatant was 
discarded. Each sample was then washed three times with water. Each sample was 
resuspended in a specific amount of polymer and water, as indicated in Table 2. The 
mixtures were stirred at room temperature for 24 hours. Sodium borohydride (0.45 g) was 
then added to each mixture and the mixtures continued to be stirred at room temperature 
for another 24 hours.  Sodium borohydride (0.45 g) was added again to each mixture and 
the samples continued stirring at room temperature for additional 24 hours. The mixtures 
were centrifuged and the supernatant was discarded. The samples were washed three 
times with water and 2.5 mL of tris buffer was added. The mixtures were stirred for 30 
minutes and then washed three more times with water. The samples were resuspended in 
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70% ethanol and incubated at -20 ˚C for at least three hours. Finally, the particles were 
aseptically washed three times with 0.9% saline and resuspended in 0.9% saline. The 
particles were then counted with a hematocytometer, and the solution was adjusted to a 
concentration of 1 x10
8
 particles/mL. 
 
2.3 Loading of GP and GLP with preformed f-MSN 
Four samples were prepared using 1 mg/mL of f-MSNs in PBS (samples MSN-4 
and MSN-5, Table 1.  A 100 µg/mL dilution of each MSN sample in PBS was prepared. 
5 µL of MSN samples was added to magnetic GPs and GLPs. Each sample was mixed 
with a blunt heat-sealed pipet tip, centrifuged, and incubated at room temperature for one 
hour. After the incubation period, the samples were placed in the -80 ˚C freezer for 
approximately five minutes and then lyophilized. Each sample was water pushed by 
adding 5 μL of water, mixing with a blunt pipet tip, centrifuging, incubating for one hour 
at room temperature, and lyophilizing. The samples were resuspended in 1 mL of 0.9% 
saline and the GPs were magnetically purified from the unbound MSN.  
The second sample was resuspended in 1 mL of phosphate buffer (no salt), with a pH of 
6.5.  Zymolyase (50 mg) was dissolved in 0.5 mL of the phosphate buffer and the 
solution was added to the GLP sample. The sample was incubated at 45 ˚C for 1 hour. 
After the incubation period the sample was centrifuged at 10000 rpm for 15 minutes. The 
supernatant was discarded and the sample was washed two times with 1 mL of water. The 
product was lyophilized and evaluated by IR, DLS/Z-potential, and Dox binding. 
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2.4 GLP in situ synthesis of MSN 
MSN synthesis inside glucan lipid particles (GLPs) was attempted using 
fluorescently labeled APTS to monitor the formation of MSN inside GLPs by 
microscopy. Optimal loading conditions (solvent, MSN reagent concentrations) were 
determined using f-APTS before attempting GLP in situ synthesis of MSN with non-
fluorescent orthosilicates.  
 
2.4.1 MSN Synthesis with F-APTS 
Loading of MSN starting materials (TEOS, f-APTS) was evaluated using organic 
solvents that efficiently penetrate the pores of GPs and GLPs.  Miscible solvent mixtures 
were prepared as shown in Table 3 
 
GP or GLP blanks (10 mg) were mixed with 50 µL of liquid from each of the 
solutions shown in Table 3. The samples were mixed using a blunt pipet tip, sonicated, 
and incubated at room temperature for 1 hour. The samples were then centrifuged, the 
supernatant was discarded, and the samples were lyophilized for four hours. A CTAB and 
NaOH solution was prepared using 0.5 g of CTAB, 2.5 mL of water, and 70 μL of 5 M 
NaOH and heated to 80 ˚C.  CTAB/NaOH solution (50 μL) was added to each sample 
and mixed immediately with a blunt pipet tip. The samples were incubated at 80 ˚C for 
two hours with periodic mixing. After the incubation period, each sample was 
resuspended in 1 mL of ethanol until the supernatant was clear. The samples were then 
lyophilized. Particles were evaluated by fluorescence microscopy for evidence of f-APTS 
trapping inside GPs or GLPs. 
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2.4.2 In situ MSN Synthesis With Optimal Loading Conditions 
FITC (3.6 mg) was dissolved in 0.5 mL of ethanol. 60 μL was added and the 
reaction was stirred for two hours in the dark. The TG loading solution was prepared. The 
solution contained 900 μL of TEOS, 100 μL of FITC-ATPS, and 90 µL of geraniol. Two 
1 mL centrifuge tubes were prepared with 100 mg of the GLP sample. 500 μL of the 
TDG solution was added to each tube. The solutions were mixed using a blunt pipet tip 
and cup sonicated. The samples were incubated at room temperature for 1 hour. The 
samples were then centrifuged for 2 minutes at 3000 rpm and the supernatant was 
discarded. The samples were lyophilized for 4 hours. A CTAB and NaOH solution was 
made containing 0.5 g of CTAB, 2.5 mL of water, and 70 μL of 5 M NaOH and was 
heated to 80 ˚C. 500 μL of the CTAB/NaOH solution was added to each tube and 
immediately missed with the blunt pipet tip. The samples were incubated for two hours 
with periodic mixing. After the incubation period, 1 mL of ethanol was added to each 
sample, the samples were then cup sonicated, centrifuged and the supernatant was 
discarded. Each sample was then resuspended in 1 mL of ethanol and centrifuged until 
the supernatant was completely clear. Finally, the samples were lyophilized.  
 
 The first sample was evaluated for particle hydration in water and the fluorescent 
sample was evaluated at 100x. The particles were sterilized in 1 mL of 70% ethanol and 
the sample was aseptically washed. The particles were counted and 1 x10
8
 part/mL 
dilutions were prepared. 
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2.4.3 In situ synthesis of non-fluorescent MSN in GLPs 
Loading solutions of TEOS, APTS, ethanol and geraniol were prepared in the 
concentrations shown in Table 4. 
 
GLP samples were prepared at the 50 mg scale. 250 µL of the indicated loading 
solution was added to each tube. The samples were mixed using a blunt pipet tip and 
sonicated. The samples were then incubated at room temperature for 1 hour. The samples 
were then centrifuged, the supernatant was removed, and they were lyophilized for 4 
hours. A CTAB/NaOH solution was prepared using 0.5 g of CTAB, 2.5 mL of water, and 
70 μL of 5 M NaOH and was heated to 80 ˚C. 500 μL of the CTAB/NaOH solution was 
added to each sample and immediately mixed with a blunt pipet tip. The samples were 
incubated for 2 hours at 80 ˚C with periodic mixing. After the incubation period 1 mL of 
ethanol was added to each sample and sonicated. The samples were centrifuged; the 
supernatant was discarded and once again the sample was resuspended in 1 mL of 
ethanol. After removing the supernatant, the samples were resuspended in a 1 mL 
mixture of 900 μL of MeOH, 50 μL of water and 50 μL of HCl. The CTAB was extracted 
from each sample by refluxing the sample overnight. Once the CTAB was removed, the 
samples were washed three times with methanol and the pellet was left at room 
temperature to dry. 
  
2.5 Binding of MSN To Surface Derivatized GPs 
MSN suspensions and GP particle suspensions were mixed in Eppendorf tubes. In 
a typical experiment, samples containing 1x10
6
 particles of either a cationic GP surface 
WORCESTER POLYTECHNIC INSTITUTE  28 
(i.e. 25 kDa PEI-GP) and a negative control (neutral GP) were evaluated with different 
MSNs. The MSN concentration was varied from 0 to 0.2 mg/mL.  0.9% saline was added 
to bring the total volume of all samples to 100 uL. All samples were incubated in the 
dark, at room temperature for at least two hours with constant stirring. Unbound MSN 
and glucan particle bound MSN fractions were purified by two methods: (1) standard 
centrifugation and (2) pelleting through a 20% sucrose cushion.  In the first method, 
samples were centrifuged for 5 minutes at 10000 rpm. The supernatant was transferred to 
a 96-well plate and the pellet was washed with 100 µL of 0.9% saline. The samples were 
once again centrifuged and the supernatant was transferred to the 96-well plate. The 
samples were then resuspended in 0.9% saline and the pellet was transferred to the plate. 
In the sucrose cushion method, the samples were carefully layered over a 100 µL 20% 
sucrose in 0.9% saline to create a two phase system with the sucrose cushion solution 
underneath the original solution containing the GPs and MSN samples. Each sample was 
centrifuged for 10 minutes at 3000 rpm and the supernatant was transferred to the 96-well 
plate. The samples were then resuspended in 200 μL of 0.9% saline and centrifuged for 5 
minutes at 10000 prm. The supernatant was transferred to the plate and the samples were 
resuspended in 200 μL of 0.9% saline. The pellet was then transferred to the 96-well 
plate. The FITC fluorescence was measured and the percent of sample bound to the GP 
pellet was evaluated. The samples with higher binding capacity and the controls were 
also evaluated under the microscope at 100x. 
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2.6 Mesoporous Silica Bound Drugs 
2.6.1 Drug Binding to pre-formed MSN 
All MSN samples listed in Table 1 were evaluated for binding of payload drugs. 
MSN suspensions (4 mg) and payload molecules (0-1 mg) were incubated in 1 mL of 
DMSO or water overnight at room temperature. The samples were then centrifuged and 
the supernatant was transferred to an Eppendorf tubes. The solvent/MSN pellets were 
lyophilized before being resuspended in 250 µL of water. The samples were then 
centrifuged and the supernatant was collected in order to measure the released drug. The 
pellets were washed two more times with water and then resuspended in 1 mL of 
methanol. The samples were left to incubate overnight as room temperature. The samples 
were centrifuged and the supernatant was collected in order to measure the amount of 
released drug. 
 
  Additionally, the MSN loading was evaluated using hydrodynamic volume 
Loading. In this method, MSN suspensions (100 μL, 20 mg/mL) were transferred in 
Eppendorf tubes. The samples were centrifuged and the excess solvent was removed 
before being lyophilized. Rif and Dox solutions were added to each sample and the exact 
volume required to swell the MSN pellet was recorded. The samples were incubated 
overnight at room temperature and then lyophilized. Each sample was washed with 1 mL 
of water until the supernatant became clear. The supernatants were collected in order to 
measure the unbound Dox or Rif. The samples were then resuspended in 1 mL of 
methanol and incubated overnight at room temperature. The samples were then 
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centrifuged and the methanol supernatant was collected in order to measure the bound 
Dox or Rif. 
 
2.6.2 Drug Binding to GLP-MSN 
Water-soluble drugs were evaluated for uptake in water and in a water/DMSO 
50:50 mixture. Water insoluble drugs were evaluated for particle uptake in DMSO and in 
a water/DMSO 50:50 mixture. GLP-MSN samples (1x10
6
 particles) or negative GLP 
control, drug solution, and solvent were mixed in order to obtain a final volume of 100 
µL. All samples were incubated at room temperature for at least an hour. After the 
incubation period the samples were centrifuged for 3 minutes at 10000 rpm and 90 µL of 
the supernatant was transferred to a 96-well plate in order to measure the unbound 
payload. The samples were washed in the original solvent mixture used to dissolve the 
payload drug. Each sample was vortexed and centrifuged at 10000 rpm for 3 minutes.  
The supernatant was transferred to a 96-well plate and another 90 µL of the solvent was 
added to each sample. The samples were vortexed, cup sonicated, and 100 µL were 
transferred to the 96-well plate. The fluorescence and UV/Vis or absorbance of each 
sample was measured.  The pellets were then transferred back into the Eppendorf tubes 
and centrifuged. The solvent was removed and the samples were resuspended in in 100 
µL of 0.9% saline. The samples were then evaluated with a fluorescent microscope for 
evidence of drug binding inside GLPs. 
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2.7 Drug Release Assays from MSN 
 Indicated amounts of Dox-MSN samples were suspended in solutions of PBS, 
Acetate Buffer, 10% FBS in PBS, 10% FBS in acetate buffer, and Ethanol. Five samples 
were created in each solution. Each sample was left to incubate in the dark for a set 
period of time: 1 hour, 3 hours, 24 hours, 48 hours, or 72 hours. At the end of the 
incubation each sample was centrifuged at 10000 rpm, the supernatant was removed to a 
96 well plate. The Dox fluorescence was then measured using the parameters of 
wavelength: 470 nm and emissions: 550 nm.  
 
2.8 Analytical methods for characterization of MSN and GPs 
2.8.1 Fourier-transform Infrared (FT-IR) spectroscopy 
IR spectra were obtained with a Nexus FT-IR spectrometer using the attenuated 
total reflectance (ATR) technique. For each sample 16-128 scans were collected with a 4 
cm
-1 
resolution. The scan range was from 4000 to 500 cm
-1
. 
 
2.8.2 Dynamic Light Scattering (DLS) and Zeta Potential Measurements. 
Size and zeta potential of MSN samples, and zeta potential of MSN-GP samples 
were determined with a Malvern Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK). Solvents and buffers were filtered through a 0.22 μm filter before 
sample preparation. A suspension of particles (1 mg/mL for MSN samples, 2x10
6
 
particles/mL for GP samples) was diluted in 1 mL of 20 mM Hepes buffer, vortexed and 
transferred to a 1 mL clear zeta potential cuvette (DTS1061, Malvern). Zeta potential was 
WORCESTER POLYTECHNIC INSTITUTE  32 
collected at 25 °C from -150 to +150 mV. The results are the average of 30 
measurements collected and analyzed with the Dispersion Technology software 4.20 
(Malvern) producing diagrams of zeta potential distribution versus total counts. DLS 
measurements were obtained from samples in the same zeta potential cells at 25 °C. The 
average of 20 measurements was collected in the size range from 1 nm to 10000 nm. The 
data was analyzed with the Dispersion Technology software producing histograms for the 
particle size versus % intensity. 
 
2.8.3 Flow Cytometry FACS 
Flow Cytometry (FACS) measurements were obtained with a Becton Dickinson 
FACS Calibur instrument (BD, Franklin Lakes, NJ). Samples were prepared for FACS 
analysis by binding of 10 uL of 0.5 mg/mL Dox-MSN to 2 x10
6
 particles. The samples 
were washed from unbound Dox-MSN and resuspended at 2 x10
6
 GP/mL in PBS. 
Unmodified GPs were used as negative controls and fluorescein labeled GPs as the 
positive control. The particles were analyzed with an FL2 laser at 550 nm by collecting 
an average of 15000 measurements. Gating and analysis was performed using FlowJo 
6.4.2 software. 
 
2.10 Dox-MSN/GP cell delivery  
 Saline, GP particle suspensions, and Dox-MSN suspensions were combined in 
indicated concentrations. GPs were used at 10 particles per cell, while Dox-MSN was 
used from 5 x10
-5
 to 5 mg/mL concentrations. The Dox/GP ratio used was 5 x10
-7 
mg to 
0.05 mg Dox per 1 x10
6
 GPs.  Different concentrations and samples of both MSN and GP 
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particles were used. 100 μL of solution was created for each cell plate. The mixture was 
then incubated at room temperature for one hour. The samples were then washed two 
times with 0.9% Saline. DMEM was added to each tube and the mixture was slowly 
mixed with a pipette. The samples were then added to the indicated cells. To test for Dox-
MSN uptake the plates were incubated for 3 hours at 37 ˚C. The cells were then fixed 
with 1% formalin in order to observe GP mediated uptake of Dox-MSN. To test for cell 
growth and cell viability the samples were incubated for 3 hours, 24 hours, 48 hours, or 
72 hours. The optimal effect was observed at 48 hours so additional experiments were 
processed at 48 hours to collect the cells and to count them.  
 
Cell culture experiments were repeated for cell lines B6 (a macrophage cell line 
with glucan receptors), 3T3-D1 (3T3 cell line modified to express glucan receptors), and 
3T3 (cells with no glucan receptor). For evaluation of growth arrest the cells were 
processed after a 48 hour incubation at 37 °C. First, the medium was removed and the 
cells were washed with sterile PBS once. Then 250 μL of sterile PBS and 25 μL of 1% 
trypsin-EDTA were added to each well to remove the cells from the well. The cell 
suspension was transferred to Eppendorf tubes and centrifuged at 1000 rpm for 10 
minutes. The PBS was carefully removed and the cells were resuspended in 100 μL of 
2% trypan blue in PBS. The cells were counted with a hematocytomer and the percentage 
of cell growth was normalized relative to the count of cells in a well incubated with only 
DMEM and 0.9% saline.  
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2.9 Biological assays for evaluation of drug-MSN/GP  
2.9.1 Minimum inhibitory concentration (MIC) assays  
100 μL of 2x Lysogeny broth (LB) was added to row A of a 96 well plate 
containing E. coli while 100 μL of 1x LB was added to all other wells. 100 μL of a 
sample was then added to the wells in row A. A serial dilution was then created with a 
multi-channel pipette by transfer 100 μL of solution from row A to row B and so forth. 
100 μL is removed from row H and discarded. A solution of 1:100 E. coli in 1x LB is 
then added to each well starting with row H. Optical Density was then recorded at 650 
nm using a microplate reader. The plate was then incubated overnight at 37 ˚C. Optical 
Density was again recorded at 650 nm using a microplate reader. 40 μL of 0.05% 
resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) was then added to each well. The 
sample was incubated at 37 ˚C until the control well showed a change in color from blue 
to pink; at this point a picture was taken.  
 
 
3. Results and Discussion 
 Methods to prepare glucan particles (GPs) containing mesoporous silica 
nanoparticles (MSNs) for small drug molecule targeted delivery to macrophages were 
completed. It was the goal of this project to synthesize GPs containing MSNs to create a 
delivery agent that benefits from the macrophage targeting capabilities of glucan particles 
and small drug molecule binding capacity of MSNs. The project began with the synthesis 
of seven different MSN samples. MSNs were then combined with GPs in three different 
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synthetic methods; (1) encapsulation of MSN inside of the GPs, (2) in situ synthesis of 
MSN within the GPs, and (3) binding of the MSNs to the exterior of the GPs. The drugs 
doxorubicin (Dox) and rifampicin (Rif) were bound to the GP-MSNs and the complexes 
were evaluated for its antimicrobial activity (Rif samples) or effect on drug delivery and 
growth arrest of 3T3-D1 and 3T3 cells.  
 
3.1 Synthesis and characterization of MSNs 
 MSNs are used in the delivery of drugs and controlled release. By developing 
MSN samples with different attached charged groups, it is possible to compare the 
delivery and release of varying MSNs with the drugs doxorubicin and rifampicin. In the 
infancy of this project, seven different samples of MSN were developed as indicated in 
Table 1. The MSN-1 sample was built as the TEOS standard while the other MSN 
samples contain either phosphate or amine or both groups to have a surface charge inside 
of the pores that will enhance binding of drugs by electrostatic interaction. The MSN 
samples were characterized by Fourier Transform Infrared Spectroscopy (FT-IR), zeta 
potential, and dynamic light scattering measurements. The samples labeled with f-APTS 
were also evaluated by fluorescence microscopy. 
 
Formation of the CTAB micelle is critical to MSN synthesis as the micelle acts as 
a template to produce a highly porous material. In the absence of this template the 
orthosilicate compounds decompose in water to form silicon dioxide (sand). A control 
sample (MSN-7) was prepared from TEOS reaction in water in the absence of CTAB. 
Comparison of MSN-7 and MSN-1 (sample density, aggregation, IR and drug 
adsorption) confirmed the successful formation of a porous material for MSN-1. 
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FT-IR of MSN before and after CTAB extraction was collected to evaluate 
complete removal of CTAB from the MSN/CTAB mixture. During the synthesis of 
MSN, CTAB was extracted from the samples creating completely porous nanoparticles. 
Figure 10 shows the IR spectra of MSN-1 before and after the CTAB extraction. The 
spectrum of the MSN-1 sample with CTAB displays a hydroxyl group at 3373 cm
-1
, this 
hydroxyl group belongs to the CTAB. The spectrum of the MSN-1 sample without 
CTAB shows no peak within that range proving the successful extraction of CTAB from 
the sample.  
 
 The IR spectrum of MSNs show absorption bands in the range of 3750-3000 cm
-1
 
due to the silanol groups. Surface functionalization of MSNs by the co-condensation 
method provides with additional vibrational bands. For examples, surface 
functionalization of the outer hydroxyl groups with APTS to form Si-O-Si bonds leads to 
a decrease in the silanol absorption band at 3750-3000 cm
-1
. The most significant band of 
the TEOS/APTS and TEOS/APTS/PO4 samples correspond to the CH2 asymmetric 
bending at 2933 and 2871 cm
-1
 and the NH2 stretching mode at 3375 cm
-1
 ( (Zhang, Zhi, 
Jiang, Zhang, Wang, & Wang, 2010). These bands are exhibited in the IR spectrums 
shown in Figure 11.  
 
The low intensity of most of the IR peaks did not allow for the complete 
characterization of the MSN samples. Clear evidence of successful synthesis was 
provided by measuring the zeta potential of each MSN sample.  
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Zeta potential is a technique that measures the outer boundary layer of ions 
formed between the solvent and a particle. This outer layer is affected by the net charge 
distribution of ions in the particle. The zeta potential results shown in Table 5 show clear 
evidence of the surface functionalization of MSN nanoparticles. MSN-1 prepared with 
TEOS has an almost neutral zeta potential. Samples containing amine groups (MSN-3, 
MSN-4) show a significant shift to a positive zeta potential (cationic MSN), while 
samples with phosphate (MSN-2) show a significant shift to a negative zeta potential 
(anionic MSN). The MSN-5 and MSN-6 samples containing both phosphate and amine 
groups show that the MSN nanoparticles are anionic, which is expected as the phosphate 
compound (PO4) was selected to have a longer alkyl chain spacer than the amine 
compound (APTS). This was done following previous work (Meng, et al., 2010) showing 
that the PO4 compound stabilizes the MSN by preventing particle aggregation due to 
amine hydrogen bonding between MSN nanoparticles in samples like MSN-3.  
 
Based on Table 5, the particle with the greatest binding capacity is the MSN 
bound with TEOS/APTS/PO4 because the zeta potential value exceeds -30 mV. Zeta 
potential has the limitation of effect of particle aggregation. Nanoparticles that tend to 
aggregate and settle will lead to a shift of zeta potential to a neutral value even if the 
sample has a high density of charged (either anionic or cationic) surface groups.  
 
Dynamic light scattering (DLS) measurements of the MSN samples collect 
information of particle size and particle size distribution. Table 5 shows both the average 
particle size and polydispersity index (PDI). PDI determines how homogenous or 
heterogeneous the sample is. The PDI is determined on a scale from 0 to 1, 0 being 
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completely homogenous and 1 being completely heterogeneous. All samples shown here 
have a high PDI, this implies a high level of heterogeneity. The amine particle size shown 
in Figure 13 represents the most common particle size value. However, the nanoparticles 
assume a broad range of sizes. Microscopic evaluation of fluorescent MSN (Figure 14) 
confirmed the heterogeneity of particle size of all samples.  
 
3.2 GP and GLP loading of pre-formed MSNs 
 The first approach to incorporate pre-formed mesoporous silica nanoparticles 
inside of the glucan particles was to load the MSN samples directly into the GPs. The 
loading of nanoparticles into glucan particles had been completed previous to this project 
allowing for a comparative reference.  Nanoparticles of less than 40 nm in diameter (i.e. 
magnetic iron oxide NPs of 10 nm in diameter, quantum dots, polystyrene nanoparticles) 
have been successfully loading inside the hollow cavity of GPs and trapped either by 
aggregation of nanoparticles or trapping of derivatized nanoparticles by crosslinking with 
a polymer by electrostatic interaction (Soto & Ostroff, Encapsulation of Nanoparticles 
Inside Yeast Cell Wall Particles for Receptor-targeted Drug Delivery, 2010).  However, 
experiments failed when attempting to reiterate the previous YCWP delivery system with 
GP loading of pre-formed MSNs. Two major issues contributing to the failure of loading 
pre-formed MSN into GPs was MSN particle size and heterogeneity. The significantly 
larger MSN nanoparticle size of 50-100 nm resulted in a small amount of MSNs being 
trapped inside of the GPs. In order to visualize the results, we used MSN/fAPTS but 
microscopy images showed approximately 1 in 100 particles loading into the GPs. In 
conclusion, the MSN samples did not have enough material of the required size to get 
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inside of the GPs so further loading strategies were undertaken in order to synthesize a 
successful drug delivery system. Next, we loaded starting materials for MSN and carried 
out the synthesis of MSN inside of the GPs. 
 
3.3 GLP in situ synthesis of MSNs 
 The MSN was synthesized inside of the GLP. By adding TEOS/APTS with 
geraniol/ethanol to the GLP the TEOS/APTS got trapped inside of the GLP. 
Geraniol/ethanol mixture was used as solvent as the silicate compounds react with water, 
the common solvent for GP payload loading.  The resulting product of water and TEOS 
would generate sand (as proved with MSN-7 control sample). Once the TEOS/APTS is 
inside of the GLP, MSN was synthesized by adding CTAB aqueous solution to the GLP 
and incubating at 80°C. GLP in situ synthesis of MSNs is a preferable drug delivery 
agent because the MSN is protected by the glucan particle. 
 
In the first generation of GLP-MSN samples, fluorescent APTS (fAPTS) was 
used to monitor the formation of MSN inside the hollow cavity of the GLPs. The 
microscopic images shown in Figure 15 shows that the MSN was successfully 
synthesized inside of GLPs. The figure is set up with the bright field image on the far left, 
the middle image is of the fluorescence, and the third image is an overlay of the two 
images. This picture shows the GLPs in the bright field image and the MSN in the 
fluorescent image, by overlaying the two pictures in the third image it is possible to see 
that the MSNs are within the GLPs. This process qualitatively proves that MSN can be 
made with in the GLPs. 
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Following optimization of MSN in situ synthesis with f-APTS, we focused our 
efforts on synthesizing GLP-TEOS/APTS/PO4 as this sample is expected to have better 
binding capacity for Dox than other GLP-MSN samples. However, the drug binding 
capacity bound inside of GLP-MSNs is not significantly higher than the GLP-TEOS or 
the empty GLPs, which was used as the negative control. These results indicate that most 
of the Dox samples bound to the glucan particle’s lipid layer rather than the MSN. 
 
 The solvent used in loading drugs into the GLP-MSNs plays a significant role in 
the amount of drug bound to the GLP-MSNs. In order to load GP-MSNs with drug the 
particles must swell. Although water is an excellent solvent in swelling GPs it does not 
have an effect on MSNs. MSNs tend to aggregate in the presence of water and pore 
permeation and encapsulation of the drug is therefore reduced. On the other hand, DMSO 
easily swells the MSNs but if the concentration of DMSO exceeds seventy percent it will 
degrade the GLPs. In an attempt to successfully load drug into the GP-MSNs, DMSO 
with a concentration of fifty percent was used as a loading solvent. The results, as shown 
in figure 16, display a significantly larger amount of drug bound to different GLP-MSN 
samples loaded in 50% DMSO in comparison to water. 
 
Figure 17 shows the maximum binding capacities at different concentrations of 
Dox. Overall the highest binding was seen in the control sample, containing no MSN. 
This was believed to have occurred because the lipid layer is still intact with the control 
GLPs, while the lipid layer in the process samples was probably no longer intact. Since it 
was difficult to preserve that layer and achieve high binding with the GLP-MSN 
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complexes it was determined that it would be more efficient to attach the MSN particles 
to the outside of the GPs rather than the inside. 
 
 Once we demonstrated that building the MSN inside of the GLP was going to 
have a limitation regarding drug binding we followed up with a strategy with which we 
attached MSN containing the drug to the outer surface of the GP. 
 
3.4   Evaluation of MSN binding to the outer surface of GPs 
Specific MSNs were developed for controlled release and drug delivery systems. 
Surface functionalized MSNs display well-defined surface properties for site-specific 
delivery and hosting molecules with various size, shapes, and functionalities. In the case 
of this project, MSNs were used in the drug delivery of doxorubicin (Dox) and rifampicin 
(Rif). By covalently binding to the drugs, MSNs are capable of delivering both drugs to 
cells containing glucan receptors.   
 
Pre-formed MSN nanoparticles were first loaded with the payload drug, evaluated 
for binding capacity and release under different pH conditions, and finally a biological 
assay was carried out for the free drug-MSN sample or bound to the surface of glucan 
particles.  
 
3.4.1 Rif-MSN 
 Two different MSN samples, MSN-1 and MSN-6, were used to look at the 
titration of Rif and observe how much Rif bound to the MSN. The results, displayed in 
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figure 18, show that the cationic MSN had a higher binding capacity. The experiment was 
then repeated at 50% loading using MSN-1, MSN-2, MSN-3, and MSN-6. The results 
can be seen in Figure 19. In an attempt to bind as much Rif to MSN as possible, we 
prepared the samples with a high concentration of Rif since a saturation point was not 
reached in the titration experiment shown in Figure 18. After the evaluation of Rif 
binding and release from MSN, the samples were tested for their effect on inhibiting the 
growth of E. coli. 
 
The Minimum Inhibitory Concentration (MIC) is the lowest concentration of an 
antimicrobial that it takes to kill a microorganism. In the case of this project, the MIC is 
determined to be the lowest concentration of Rif-MSN that is needed to kill more than 
90% of the E. coli. Referring to Table 6, Rif-MSN 1 had no effect on the E. coli. The 
reason why the E. coli remained unharmed is because MSN-TEOS has high aggregation 
in water making it nearly impossible to resuspend.  The most successful Rif-MSN was 
sample 4 because the MSN-TEOS/APTS/TEOS has a MIC at 3.125 mg/mL. The MSN-5 
(no Rif) was used as MSN control, which is predicted to not have an effect on the E. coli 
because it is not a toxic material. Looking at Table 6, there is a false positive result 
showing that the MSN control is killing the E. coli. It is possible to receive false positives 
because MIC assay calculations are based from light absorption readings. However, 
absorption is sensitive to the presence of particles; a high concentration of particles cause 
light scattering so the sample absorbance or optical density is not the only measurement.  
 
In reaction to the false positive results, a secondary assay was compared to the 
absorption measurements in order to determine which Rif-MSN samples are actually 
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killing E. coli. Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) is an oxidation-
reduction indicator used in cell viability assays for bacteria and mammalian cells. By 
adding resazurin, one can observe the dramatic change in color between the dead and 
alive E. coli. As observed in Figure 20, the TEOS control shows no evidence of dead E. 
coli proving that the absorption of the MSN-TEOS control is a false positive. However, 
all other results hold true to the absorption results (Carter, Gaspar, & Leise, 1955).  
 
Rif-MSN samples were not evaluated for binding to the GP surface and GP 
mediated delivery of Rif-MSN into cells expressing glucan receptors. The reason why 
these experiments were not pursued is because the original concentration of nanoparticles 
was 50 mg/mL, which is significantly large. The lowest possible concentration of Rif-
MSN that will have an effect on killing the E. coli is 3 mg/mL, which is still a very large 
concentration of nanoparticles. This concentration is not ideal when using GP because 
only a very small percentage of the Rif-MSN will bind to the GP and will have little to no 
affect at all on the E. coli. With such little drug concentration the GP will deliver the Rif-
MSN into the cells but it will take a long time to see any inhibition in E. coli growth.  
 
3.4.2 Dox-MSN 
The binding capacity of Dox to MSN plays an extremely important role in the 
inhibition of cell growth in a specific amount of time. A higher percentage of Dox bound 
to MSN is a result of binding to an anionic MSNs. Experimentally; two MSNs were 
created and compared. The first MSN was attached to a TEOS group, resulting in a 
neutral charge. The second MSN was attached to a TEOS/APTS/PO4 group, which has 
WORCESTER POLYTECHNIC INSTITUTE  44 
the negative phosphate groups more accessible for binding. By adding a charge to the 
MSN, a significantly greater percentage of Dox bound to the MSN. These results prove 
that a negatively charged group attached to MSN increases the amount of drug being 
carried.  
 
As shown in Figure 21, the amount of Dox that bound to MSN-TEOS/APTS/PO4 
was approximately 6 fold higher than the amount of Dox bound to MSN-TEOS. Dox 
holds a positive charge that is highly attracted to negatively charged particles. A 
negatively charged phosphate group was added to the MSN-TEOS/APTS in order to the 
give the MSN an overall negative charge.  
 
The kinetics of Dox release from Dox-MSN samples was evaluated at different 
pH conditions. It is expected the samples to be stable in PBS (pH 7) and to show an 
increase in Dox release rate with low pH. This ideal release behavior would facilitate 
drug endosomal release upon uptake of the Dox-MSN-GP conjugates by cells. As seen in 
Figure 23, the samples show a slightly faster release at pH 5 or pH 2 relative to pH 7. 
However the amount of Dox release over 60 hours is only 10% of the original input. 
Samples were evaluated over longer periods of time (up to 7 days) without a significant 
increase in Dox release. This is likely the result of the MSN pores not allowing for 
efficient drug diffusion of the drug out of the pores when placing the MSN sample in 
aqueous solutions.  Similar effect as the one shown in Figure 23 was observed for 
samples incubated at the same pH values with 10% fetal bovine serum (FBS).  
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Following optimization of Dox binding to MSN and evaluation of Dox release, 
the Dox-MSN samples prepared with MSN-6 were evaluated for binding to GPs and 
targeted cell delivery.  
 
Dox-MSN samples were bound to two different GPs (neutral GPs and 25 k PEI-
GP) and the binding was evaluated by FACS, zeta potential, and fluorescent microscopy.  
 
Measurements of the zeta potential provided clear evidence that the Dox bound 
inside of the MSN. MSN samples were loaded with Dox in DMSO and then washed with 
water to remove Dox bound on the surface. This can be concluded because the zeta 
potential curve of MSN only had a very slight shift to the left when bound with Dox as 
shown in Figure 24. If the Dox had indeed bound to the outside of the particle than there 
would have been a very significant shift in the zeta potential curve. 
 
The Dox-MSN samples were then bound to glucan particles. Figure 25 shows that 
25 kPEI-GPs have a positive zeta potential. When Dox-MSN is bound with the 25k PEI-
GP the zeta potential shifts to the left. Based on this observation, one can conclude that 
the Dox-MSN is bound to the surface of the GPs. The presence of only one peak for the 
DoxMSN-25kPEI-GP sample and microscopic evaluation confirm the preparation of 
samples that are free of unbound Dox-MSN.  
 
 Figure 25 also shows the zeta potential of GPs and GP conjugated with Dox-
MSN. GPs have a neutral zeta potential. The magnitude of the shift for the Dox-MSN/GP 
sample is less than 10 mV relative to the zeta potential of GP. In comparison the shift for 
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the Dox-MSN/25kPEI-GP is almost 50 mV from the original zeta potential of 25kPEI-
GP.  This confirms that the Dox-MSN is effectively bound to the 25k PEI-GP, but not to 
the neutral GP. In theory, there should not be a shift in the zeta potential values when 
attempting to bind Dox-MSN with a neutral GP. The reason why the peak shifts slightly 
to the left is because of unavoidable experimental error. In order to wash the non-bound 
nanoparticles from a mixture of glucan particles and nanoparticles the mixture is 
centrifuged and the nanoparticles should remain in suspension. However, GPs act as a 
barrier to the nanoparticles as they attempt to resuspend in solution because the size of 
GPS are significantly larger than MSNs. The nanoparticles remained trapped under the 
GPs so the GP pellet can never be washed purely. Over time, as the GPs hold the MSNs 
down, the particles will eventually bind.  
 
In addition to the zeta potential measurements, FACS analysis and fluorescent 
microscopy confirm more selective binding of Dox-MSN-6 to 25k PEI-GPs over the GP 
control.  
 
As seen in Figure 26, the plot of Dox-MSN and 25 kPEI-GP shows one distinct 
peak. This peak represents a homogeneous sample and shows that all of the GPs are 
fluorescent. In order for the GPs to be fluorescent there must be at least one Dox-MSN 
attached to it.  
 
 Figure 26 also displays a plot of Dox-MSN and GP, which consists of a few 
different peaks. These peaks represent a heterogeneous sample and can be a result of 
experimental error or Dox-MSN binding to the residual chitosan in glucan particles. 
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When the mixture of GP and Dox-MSN is washed ideally the nanoparticles are suppose 
to suspend in the liquid leaving a pellet of GPs. However, the size of the GPs trap the 
nanoparticles causing the remaining pellet to be slightly impure. Another explanation for 
the multiple peaks could be the positively charged chitosan groups in glucan particles. 
GPs consist of 1% cationic chitosan groups that are attracted to the negative charge in 
Dox-MSN.  
 
The binding of Dox-MSN to GPs was also confirmed by fluorescence microscopy 
(Figure 27). Imaging the samples for Dox fluorescence at the same image acquisition 
gain it clearly shows a brighter sample for the Dox-MSN bound to 25k PEI-GP compared 
to the neutral GP. In the case of neutral GPs the fluorescent Dox-MSN bound to the 
particles is minimal and can only be seen with high exposure times (10-15 sec) or the 
Dox-MSN is present in the particles as large aggregates not associated with glucan 
particles. 
 
Following the characterization of the Dox-MSN-GP samples we tested the 
samples for efficiency to deliver Dox into NIH-3T3-D1 cells. This cell line has been 
genetically modified to express glucan receptors and efficiently phagocytose GPs.  
 
In Figure 28 the GP mediated delivery of Dox is observed in 3T3-D1 cells after 
three hours of incubation. However, those same results are not shown with the Dox-MSN 
sample. The reason why these results differ are because the GPs are mediating delivery 
but at three hours there is not enough time for the nanoparticles (free Dox-MSN) to be 
internalized by cells through different particle uptake mechanisms. However, at 24 hours 
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there is much less difference in the fluorescence between samples delivered with and 
without GPs as there has been enough time to for endocytosis of free MSN.  
 
Once shown that the Dox can be delivered into the cells using the MSN-GP we 
evaluated  the effect of the these Dox samples on cell viability. At high Dox-MSN 
concentration it was possible to show complete inhibition of 3T3-D1 cell growth. 
However, at this concentration Dox-MSN delivery was not mediated by glucan particles. 
A Dox-MSN titration allowed to identify optimal conditions showing GP mediated 
delivery of Dox-MSN into cells. The experiments were done following two procedures. 
In the first method, the Dox-MSN/GP samples were added to cells and incubated for 3 
hours. After this 3 hour incubation the DMEM medium was removed from the cells and 
fresh DMEM added. The DMEM collected after 3-hour incubation (“supernatant”) was 
transferred to another well and the cells incubated for additional 48 hours. This strategy 
allowed for evaluation of the effect of sample internalized by cells after 3 hours 
(minimum time required for efficient GP uptake by 3T3-D1 cells) and also evaluation of 
effect of Dox-MSN or Dox-MSN/GP sample remaining in the medium after the 3 hour 
incubation. In the second method the medium was not changed until 24 hour incubation 
allowing for uptake of GPs, but also likely for uptake of free Dox-MSN or free Dox by 
other uptake mechanisms.  
 
The results shown in Figure 29 (“supernatant”) and Figure 30 (3 hour incubation) 
show the effect of glucan particle mediated delivery to cells at low Dox-MSN 
concentration. At this low concentration (5e
-5
 mg of Dox-MSN per 1x10e
6
 GPs) it was 
not possible to effectively kill the cells, but a significant (50%) effect on growth arrest 
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was measured for Dox-MSN delivered via 25k PEI-GP samples compared to GP or free 
MSN. The Dox-MSN delivered by 25 k PEI-GP shows a clear effect after 3 hour 
incubation and there is not enough free Dox or free Dox-MSN remaining in the 
supernatant to show growth arrest. 
 
There is no difference in cell growth with the supernatant because there was 
100% cell growth at a low concentration of Dox-MSN. 
 
When the media (DMEM) was changed at 3 hours you can observe a significant 
difference in cell growth for 25k PEI-GP. This information demonstrates that 25 kPEI-
GP is binding with Dox-MSN at concentration 0.0005 mg/mL. 
 
Samples incubated for 24 hours (Figure 31) did not show a clear effect of GP 
mediated delivery of Dox-MSN even at low concentrations. Following a 24 h 
concentration it is likely that the Dox-MSN particle aggregates or Dox released from 
Dox-MSN or Dox-MSN/GP will accumulate in cells to a significant concentration to 
have an effect on growth arrest. 
 
Additionally, Dox-MSN was delivered with and without GPs to 3T3 cells, which 
do not express glucan receptors. Following particle uptake for 3 h the DMEM medium 
was replaced in the wells to remove any GP or free MSN particles still not internalized by 
the cells. The cells were incubated for additional 48 hours and evaluated for Dox effect 
on cell growth. The results shown in Figure 32 indicate that Dox-MSN delivered using 25 
k PEI-GP have an effect on growth arrest on 3T3-D1 cells, but not on 3T3 confirming 
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that GP mediated uptake is responsible for Dox delivery. In comparison, free MSN show 
an effect on both 3T3 and 3T3-D1 cells.  
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4. Conclusion 
This project led to the successful synthesis of seven different MSN samples. The 
MSN’s capacity to bind to both doxorubicin and rifampicin were analyzed. It was 
concluded that the most successful method of binding MSNs and GPs was to attach 
phosphate functionalized MSNs to the outside of cationic PEI-GPs. This process had 
limitations in the level of Dox that was being bound. Dox-MSN-GP formulations show 
GP mediated delivery of Dox into 3T3- D1 cells causing growth arrest, but no cell death.  
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5. Future Work 
The particles generated during the course of this project were designed to deliver 
Rifampicin (Rif) and Doxorubicin (Dox) to target cells. Through the background 
information and experimental data gathered during this project, technology can be further 
developed for more specific and efficient GP-MSN delivery systems.   
 
The synthesis of MSN can be changed in the future to create a particle with a 
higher binding affinity for the target drugs Rif or Dox. Further changes in MSN synthesis 
can also be used to create samples for pH (i.e. polyacrylic acid modified MSN), 
thermosensitive (i.e. poly(N-isopropylacrylamide) modified MSN) or redox (i.e. 
cystamine modified MSN) controlled release of drugs.  
 
Changes in MSN synthesis can also be used to generate more uniform MSN 
particles. By controlling the size of the particles being created, particles smaller than 
~40nm can be generated that would be able to be trapped within the GPs, rather than just 
binding on the surface. This would allow for more drugs to be encapsulated per GP.  
 
The last technique that can be developed from our work is specifically used for 
the delivery of Dox to tumor sites. By adding a magnetic binding capacity Dox would be 
security locked inside of the MSN. Once the macrophage cells uptake the GP-MSNs they 
retain them for a long period of time. Throughout the process, macrophages migrate into 
tumors and multiply. Once enough of the macrophage cells loaded with GP-MSNs have 
entered the tumors, the released drug will inhibit cell growth and eventually kill the cells. 
WORCESTER POLYTECHNIC INSTITUTE  53 
In the case of this project, the goal was to load cells with Doxorubicin which, when 
enough Dox was delivered to the macrophage cells, would eventually kill the 3T3-D1 
cells. The drug would be released by adding a microwave directly over the site of the 
tumor. This wavelength would cause degradation of the MSN and the release of the drug 
in the target area. GP-MSNs have cell receptors that attract macrophage cells. 
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Appendix: Figures 
 
FIGURE 1: TRANSMISSION ELECTRON MICROSCOPE (TEM) IMAGES OF BAKER’S YEAST AND 
HOLLOW GLUCAN PARTICLES. SCHEMATIC REPRESENTATION OF A GP. 
 Figure 1 illustrates the process of chemically treating Baker’s Yeast cells in order 
to achieve the hollow, porous glucan particles (GPs). The chemical composition is also 
indicated.  
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FIGURE 2: DECTIN-1 MEDIATED RECEPTOR UPTAKE OF FLUORESCENTLY LABELED GLUCAN 
PARTICLES BY BONE MARROW DENDRITIC CELLS (BMDC). CELLS FROM A WILD TYPE 
(WT) MOUSE EFFICIENTLY PHAGOCYTOSE GPS. THE D1 KNOCK OUT BMDCS DO NOT SHOW 
PARTICLE UPTAKE. ADDITION OF A SOLUBLE B-GLUCAN, LAMINARIN, INHIBITS GP UPTAKE 
(HUANG H. , OSTROFF, LEE, SPECHT, LEVITC, & WANG, 2009).   
 Figure 2 shows fluorescent microscope images superimposed over bright field 
images. The wild type Bone Marrow Dendritic Cells (WT BMDCs) show uptake of the 
fluorescent glucan particles while the BMDC with the glucan receptor (D1) knocked out 
did not show uptake. Wild type mouse cells also showed glucan uptake, but no uptake in 
the D1 knockout cells.  
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FIGURE 3: GP FORMULATIONS SHOWING POSSIBLE LOCATIONS OF PAYLOAD 
MACROMOLECULES USING POLYPLEX CORE SYNTHESIS AND LAYER-BY-LAYER (LBL) 
ELECTROSTATIC ASSEMBLY 
 Figure 3 illustrates the different compositions of glucan particles.  
 
 
FIGURE 4: SCHEMATIC REPRESENTATION OF PREFORMED CARBOXYLATED POLYSTYRENE 
NANOPARTICLE LOADING: (A) INSIDE GPS, (B) ON THE SURFACE OF A CATIONIC GP. (20NM 
NPS ARE SHOWN IN GREEN CIRCLES AND 200NM NPS IN RED CIRCLES) (SOTO & OSTROFF, 
ENCAPSULATION OF NANOPARTICLES INSIDE YEAST CELL WALL PARTICLES FOR 
RECEPTOR-TARGETED DRUG DELIVERY, 2010) 
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Figure 4 shows two possibilities for binding nanoparticles and glucan particles. 
The first possibility is loading the nanoparticles into the glucan particle and the second 
option is loading the nanoparticles on the outside of the glucan particles. Microscopic 
images are also shown of this process.  
 
 
FIGURE 5: SCHEMATIC REPRESENTATION OF MSN SYNTHESIS USING TETRAETHYL 
ORTHOSILICATE (TEOS) 
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 Figure 5 shows the process of synthesizing MSN. A CTAB micelle is shown as a 
template with the orthosilicates arranging themselves around the micelle in a spherical 
orientation.   
 
 
FIGURE 6: FIELD EMISSION SCANNING ELECTRON MICROSCOPY (FESEM) IMAGES OF NANO-
ROD (LEFT) AND NANO-SPHERICAL (RIGHT) MSNS (HUH, WIENCH, YOO, PRUSKI, & LIN, 
2003). 
 Figure 6 shows microscopic images of the two possible MSN structures. The first 
is the spherical shape which was used for this project; the other is a rod composition.  
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FIGURE 7: SCHEMATIC REPRESENTATION OF THREE STRATEGIES TO INCORPORATE MSN 
INTO GLUCAN PARTICLES: (1) ABSORPTION OF MSN <40NM THROUGH THE GLUCAN 
PARTICLE PORES, (2) LOADING OF MSN REAGENTS FOR IN SITU SYNTHESIS OF 
NANOPARTICLES, (3) ELECTROSTATIC BINDING OF ANIONIC MSNS TO CATIONIC GPS. 
 Figure 7 shows the three different strategies taken for this project to create 
GP/MSN complexes. The first process includes putting preformed MSNs inside the GPs. 
The second process would involve synthesizing the MSNs inside of the GPs. The third 
process would involve functionalizing the outside of the GPs and attaching the MSNs to 
the surface of the GPs.  
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FIGURE 8: THE CHEMICAL STRUCTURE OF RIFAMPICIN 
Figure 8 shows the chemical structure of the Tuberculosis drug Rifampicin (Rif).  
 
 
FIGURE 9: THE CHEMICAL STRUCTURE OF DOXORUBICIN 
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Figure 9 shows the chemical structure of the cancer drug Doxorubicin (Dox). 
 
Table 1 shows the composition of each of the MSN samples.  
 
TABLE 1: COMPOSITION OF MSN  SAMPLES 
 
Table 2 shows the conditions necessary to create cationic glucan particles.  
 
TABLE 2 REACTION CONDITIONS TO PRODUCE CATIONIC GLUCAN PARTICLES (15 MG 
SCALE). 
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Table 3 shows the loading solvent mixtures that were used when attempting to 
synthesize MSN within the GPs.  
 
TABLE 3: LOADING SOLVENT MIXTURES EVALUATED FOR IN SITU SYNTHESIS OF MSN. 
 
Figure 4 shows the optimal loading solvent concentrations.  
 
TABLE 4: OPTIMAL LOADING SOLVENT MIXTURES FOR IN SITU SYNTHESIS OF MSN. 
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FIGURE 10: IR SPECTRUM OF MSN1 BEFORE (TOP) AND AFTER (BOTTOM) CTAB 
EXTRACTION 
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 Figure 10 includes the IR spectra for MSN1 before and after the CTAB micelle 
extraction. The upper figure shows a broad band at 3373 indicating the presence of 
CTAB; this band is not present in the lower figure.   
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FIGURE 11: IR SPECTRA OF MSN-3 (TOP) AND MSN-6 (BOTTOM) 
 Figure 11 shows the IR spectra for samples MSN-3 and MSN-6 indicating the 
presence of different functional groups.  
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 Table 5 includes the zeta potential and DLS size measures for all MSN samples.  
 
TABLE 5: ZETA POTENTIAL AND DLS SIZE MEASUREMENTS OF MSN SAMPLES 
 
 
FIGURE 12: ZETA POTENTIAL OF MSN SAMPLES 
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 Figure 12 graphically illustrates the data presented in table 5; particle count is 
graphed versus zeta potential for samples MNS-1, MSN-3, and MSN-6.This graph 
indicates the difference in zeta potential depending on the different functional groups.  
 
 
FIGURE 13: PARTICLE SIZE OF MSN SAMPLES 
Figure 13 shows the particle size of three different MSN samples versus the 
intensity of the particles.  
 
 
FIGURE 14: 20X MICROSCOPIC IMAGES OF MSN  PREPARED WITH TEOS AND F-APTS 
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 Figure 14 shows the brightfield image of the MSNs prepared with TEOS and F-
APTS, the fluorescent image of fluorescent MSNs, and an overlay of the two images. 
This image is used to show the successful synthesis of fluorescent MSN.  
 
 
FIGURE 15: F-MSN (TEOS/F-APTS) SYNTHESIS INSIDE GLP 
 Figure 15 shows the brightfield image of the GLPs, the fluorescent image of 
fluorescent MSNs, and an overlay of the two images. In the overlaid image is it possible 
to see that MSN samples were synthesized with in the GLPs.  
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FIGURE 16 : PERCENT OF DOX BOUND INSIDE OF DIFFERENT GP-MSN SAMPLES LOADED IN 
WATER (TOP) AND 50% DMSO (BOTTOM) 
 Figure 16 shows the amount of Dox bound to different GP-MSN samples. The top 
image shows loading in water, the amount of Dox bound is negligible due to MSNs 
tendency to shrink in water. The bottom image shows the samples loaded in 50% DMSO 
50% water. The amount of Dox bound was more significant though it never reached over 
0.01% Dox bound.  
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FIGURE 17: PERCENT OF DOX BOUND INSIDE OF DIFFERENT GLP-MSN SAMPLES WHEN 
LOADED IN 50% DMSO 
 Figure 17 shows the percent of Dox bound at different percent weight to weight 
targets for two samples of MSN and GLP controls. The GLP control showed the highest 
amount of Dox bound. These results indicate that this method was unsuccessful.  
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FIGURE 18: PERCENT OF RIF BOUND TO (A) MSN-1: TEOS AND (B) MSN-6: 
TEOS/APTS/PO4 
 Figure 18 shows the percentage of Rif that bound to a neutral MSN and an 
anionic MSN. The anionic MSN showed overall higher binding capacity.  
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FIGURE 19: PERCENT OF RIF BOUND TO FOUR DIFFERENT MSN SAMPLES 
 Figure 19 shows the percent of Rif bound to 4 different MSN samples. The 
highest binding was seen in sample MSN-2.  
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Table 6 shows the concentrations of Rif-MSNs used during the MIC assay.  
 
TABLE 6: RIF-MSN MIC ASSAY 
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FIGURE 20: MIC PLATES WITH COLUMNS IN REFERENCE TO TABLE 6  
 Figure 20 shows the MIC plate. The samples added to each well are indicated in 
Table 6. In this assay cell death is indicated by blue wells while live cells are indicated by 
pink wells. Column 7 was used as a control to show the capacity for Rif to kill E. coli 
cells. The best results were seen from MSN-3-Rif and MSN-2-Rif.  
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FIGURE 21: PERCENT OF DOX BOUND TO (A) MSN-1 AND (B) MSN-6 
 Figure 21 shows the percent of Dox bound to sample MSN-1` and MSN-6. The 
anionic MSN-6 had much higher binding with the Dox compared to the MSN-1.  
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FIGURE 22: THE PERCENT OF DOX BOUND TO (A) MSN-1 AND (B) MSN-6  
 Figure 22 shows the percent of Dox bound to sample MSN-1` and MSN-6. The 
anionic MSN-6 had much higher binding with the Dox compared to the MSN-1.  
 
  
 
WORCESTER POLYTECHNIC INSTITUTE  81 
 
FIGURE 23: THE EFFECT OF PH ON DOX RELEASE FROM MSN-6. 
 Figure 23 shows the effect of pH on Dox release over time. The samples are most 
stable at pH 7 and show faster release at pH 5 and 2.  
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FIGURE 24: ZETA POTENTIAL RESULTS OF DOX BINDING TO MSN-6 
 Figure 24 shows the difference in zeta potential for MSN-6 (TEOS/APTS/PO4) 
and MSN-6 bound to Dox. There is a shift to the left when Dox is bound indicating that 
the sample has become more negative with the addition of the anionic nano drug particle. 
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FIGURE 25: ZETA POTENTIAL OF DOX-MSN BOUND WITH 25K PEI-GP (TOP) AND GP 
(BOTTOM) 
 Figure 25 shows two sets of data for the zeta potential of the GP and GP-MSN-
Dox complex. The upper figure shows the complex where the GP has been functionalized 
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while the lower figure shows the GP with no functionalization. There is a larger shift in 
the upper figure indicating that more MSN- Dox was bound.  
   
 
 
FIGURE 26: FACS RESULTS SHOWING SELECTIVE BINDING OF DOX-MSN TO 25 K PEI-GP 
 Figure 26 shows the results of FACS assay. These figures indicate the selective 
binding of Dox-MSN to the functionalized GP sample.  
Dox-MSN	+	25	kPEI-GP	 Dox-MSN	+	GP	
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FIGURE 27: FLUORESCENT MICROSCOPY IMAGES SHOWING BINDING OF DOX-MSN TO 25 
KPEI-GP (TOP) AND TO GP (BOTTOM)  
 Figure 27 shows microscopic images showing the binding of Dox-MSN to the 
functionalized GP (top) and the non-functionalized GP (bottom). Binding is only seen in 
the upper functionalized sample, showing the increased binding affinity with the PEI 
functionalization.  
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FIGURE 28: 20X FLUORESCENT MICROSCOPIC IMAGES SHOWING GLUCAN PARTICLE 
MEDIATED DOX DELIVERY INTO 3T3-D1 CELLS  
 Figure 28 shows the glucan particle mediated Dox delivery into 3T3-D1 cells. 
Indicating that the GP-25k PEI  is more efficient in drug delivery due to this 
functionalization.  
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FIGURE 29: AVERAGE CELL GROWTH OF DIFFERENT DOX-MSN CONCENTRATIONS IN 
SUPERNATANT 
Figure 29 shows the cell growth in the supernatant when different concentrations 
of Dox-MSN are applied. Higher concentrations showed lower levels of cell growth.  
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FIGURE 30: AVERAGE PERCENT OF CELL GROWTH OF DIFFERENT DOX-MSN 
CONCENTRATIONS AFTER 3 HOURS. 
 Figure 30 shows the cell growth when different concentrations of Dox are applied 
after 3 hours. The 25k PEI-GP-MSN drug complex showed the most cell growth 
inhibition, at the lowest concentration.  
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FIGURE 31: AVERAGE PERCENT OF CELL GROWTH OF DIFFERENT DOX-MSN 
CONCENTRATIONS AFTER 24 HOURS. 
Figure 31 shows the cell growth when different concentrations of Dox are applied 
after 24 hours. Results again indicate that the 25k PEI-GP-MSN drug complex showed 
cell growth inhibition at the lowest drug concentration.  
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FIGURE 32: AVERAGE PERCENTAGE OF CELL GROWTH OF DOX-MSN AT A CONCENTRATION 
OF 0.5 MG DOX-MSN/ML 
 Figure 32 shows the average cell growth, data is presented for 3T3 cells with and 
without the glucan receptor (D1). The data presented showed higher growth inhibition in 
cells containing the glucan receptor.  
 
FIGURE 33: DOX EXCITATION SPECTRUM 
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FIGURE 34: DOX EMISSION SPECTRUM 
These figures show the Doxorubicin excitation/emission fluorescence spectra. 
The emission and excitation spectrum of Dox, as shown in figures 33 and 34, was 
measured to verify that the purchased compound was pure.  
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FIGURE 35: ABSORBANCE SPECTRUM OF RIF IN WATER 
Figure 35 shows the visible absorption spectrum of rifampicin. This was 
completed to ensure that the sample was pure.  
 
